

RESEARCH MONOGRAPH . COMPOUND PROFILE

ISX-9

A synthetic isoxazole carboxamide identified through phenotypic screening for neuronal cell fate activation, distinguished by calcium-dependent MEF2 de-repression, NeuroD1 induction, Wnt/beta-catenin signaling through Axin1/LRP6 modulation, and proneurogenic activity in the adult hippocampus with demonstrated cognitive enhancement in rodent behavioral models.

DOCUMENT	KDC-MN-1637
ISSUED	2026-05-21
REVISION	1.0
AUTHOR	Kodiac biolabs Research
COMPOUND CLASS	Isioxazole-based small molecule neurogenic agent with Wnt/beta-catenin pathway activation and GPR68 agonism

RESEARCH USE ONLY

ABSTRACT

ISX-9 (Isoxazole 9; N-cyclopropyl-5-(thiophen-2-yl)isoxazole-3-carboxamide; CAS 832115-62-5) is a synthetic small molecule originally identified in a high-throughput phenotypic screen for compounds that activate neuronal cell fate in adult neural stem/progenitor cells, reported by Schneider et al. in 2008 in *Nature Chemical Biology* [1]. The compound triggers robust neuronal differentiation through a calcium-dependent signaling cascade: ISX-9 induces calcium influx via voltage-gated calcium channels and N-methyl-D-aspartate (NMDA) receptors, which activates calcium/calmodulin-dependent protein kinase II (CaMKII), promotes phosphorylation-dependent nuclear export of histone deacetylase 5 (HDAC5), and thereby de-represses myocyte-enhancer factor 2 (MEF2)-dependent transcription of neuronal genes including *NeuroD1* [1, 2]. Subsequent mechanistic characterization identified ISX-9 as a potent activator of the Wnt/beta-catenin signaling pathway through promotion of the association between low-density lipoprotein receptor-related protein 6 (LRP6) and Axin1, resulting in beta-catenin stabilization and upregulation of Wnt target genes [3]. A parallel line of investigation established ISX-9 as a ligand of GPR68 (OGR1), a proton-sensing G protein-coupled receptor expressed in hippocampal neural stem cells, providing a molecular target that links the proneurogenic activity to extracellular pH sensing in the neurogenic niche [4].

In vivo, ISX-9 crosses the blood-brain barrier and promotes neurogenesis in the subgranular zone of the hippocampal dentate gyrus in adult mice and rats. The Petrik et al. (2012) study in *The*

FASEB Journal demonstrated that systemic ISX-9 administration (20 mg/kg intraperitoneally) enhanced proliferation and differentiation of hippocampal subgranular zone neuroblasts, increased dendritic arborization of adult-generated dentate gyrus neurons, and improved spatial memory performance in the Morris water maze, with all effects dependent on MEF2 isoform expression in neural stem cells [2]. The compound has been investigated across a surprisingly broad range of preclinical applications beyond hippocampal neurogenesis: protection against methamphetamine relapse through modulation of abstinence-induced neurogenesis in the dentate gyrus [5]; induction of enteroendocrine cell differentiation in mouse and human intestinal organoids through upregulation of neurogenin 3 (Ngn3), NeuroD1, and Pax4 [6]; activation of Wnt/beta-catenin-dependent hair follicle cycling and hair regrowth in C57BL/6J mice [3]; and, most recently, neuroprotection and cognitive rescue in the 5xFAD transgenic mouse model of Alzheimer's disease through Wnt/beta-catenin pathway activation in hippocampal neurons [7].

ISX-9 has not entered human clinical trials. No human pharmacokinetic, safety, or efficacy data exist. The compound remains a research tool, albeit one with an expanding preclinical evidence base across neurodegenerative, addiction, regenerative, and endocrine lineage specification applications. Investigators should note that ISX-9 exerts differential effects on distinct progenitor populations: it promotes neuronal differentiation of neural stem/progenitor cells but is cytotoxic to oligodendrocyte precursor cells and inhibits angiogenic tube formation in endothelial progenitor cells at comparable concentrations [8]. This cell-type specificity has implications for interpretation of in vivo effects and for combination research in central nervous

system injury models where multiple progenitor populations contribute to repair. The compound is commercially available from multiple research chemical suppliers at greater than 98 percent purity and is typically supplied as a solid for reconstitution in dimethyl sulfoxide. This monograph reviews the chemistry, discovery, multi-pathway pharmacology, preclinical evidence base, comparative positioning against five neurogenesis-promoting small molecules (P7C3, NSI-189, BDNF mimetic 7,8-DHF, CHIR99021, and Dihexa), and practical considerations for laboratory use.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

Common name: ISX-9 (Isoxazole 9; Isx-9; ISX9).

Chemical Abstracts Service registry number: 832115-62-5.

International Union of Pure and Applied Chemistry name: N-cyclopropyl-5-(thiophen-2-yl)isoxazole-3-carboxamide.

Development codes: None. ISX-9 was identified through academic phenotypic screening and has not entered pharmaceutical development. The compound is designated by its screen identifier (Isoxazole 9) from the original Schneider et al. (2008) isoxazole library [1].

Supplier catalog identifiers: Tocris 4439; Cayman Chemical 16165; Selleck Chemicals S6625; MedChemExpress HY-12585; Sigma-Aldrich (Ambeed) AMBH303C56F8; STEMCELL Technologies 73202; Enzo Life Sciences. Multiple additional suppliers carry the compound under the ISX-9 or Isoxazole 9 designation.

1.2 Structural class and chemistry

ISX-9 belongs to the isoxazole carboxamide class. The core scaffold is a 3,5-disubstituted isoxazole ring bearing a carboxamide at the 3-position and a thiophen-2-yl (2-thienyl) group at the 5-position. The carboxamide nitrogen carries a cyclopropyl substituent. The compound is a low molecular weight, drug-like small molecule that satisfies Lipinski's rule of five and exhibits favorable central nervous system penetration properties consistent with its demonstrated ability to cross the blood-brain barrier in rodents [2].

Molecular formula: C₁₁H₁₀N₂O₂S.

Molecular weight: 234.28 g/mol.

Exact mass: 234.0463 g/mol (monoisotopic).

Physical properties: Off-white to pale yellow solid. Soluble in dimethyl sulfoxide (DMSO) at concentrations of 50 mg/mL or greater; sparingly soluble in aqueous media at neutral pH. Storage as a dry solid at minus 20 degrees Celsius under desiccation is recommended by most suppliers for long-term stability [9].

Stereochemistry: ISX-9 contains no stereocenters and is supplied as a single constitutional isomer. No enantiomeric or diastereomeric considerations apply.

1.3 Synthesis

ISX-9 is synthesized through standard isoxazole ring construction chemistry. The published approach proceeds via 1,3-dipolar cycloaddition or condensation of a hydroxylamine-derived nitrile oxide with a suitable dipolarophile or beta-keto system to form the isoxazole core, followed by carboxamide coupling. The thienyl substituent at the 5-position is introduced through use of 2-thiophenecarbaldehyde or a thienyl-substituted precursor in the ring-forming step. The cyclopropylamine carboxamide is installed by standard amide bond formation (carbodiimide coupling, acid chloride, or active ester) between isoxazole-3-carboxylic acid and cyclopropylamine [1]. The compound was originally identified from a commercial isoxazole library screened at the University of Texas Southwestern Medical Center; the synthetic route for scale-up is straightforward and the compound is manufactured at research scale by multiple chemical suppliers. Purity is typically confirmed by high-performance liquid chromatography (HPLC) and nuclear magnetic resonance (NMR) spectroscopy, with commercial lots routinely achieving greater than 98 percent area-percent purity.

2. Abstract

ISX-9 (N-cyclopropyl-5-(thiophen-2-yl)isoxazole-3-carboxamide) is a synthetic small molecule identified in a 2008 phenotypic screen for activators of neuronal cell fate in adult neural stem/progenitor cells (NSPCs) [1]. The compound operates through a multi-pathway mechanism centered on calcium-dependent de-repression of the MEF2 transcription factor family, which drives expression of the master neurogenic transcription factor NeuroD1 and downstream neuronal differentiation programs. Parallel and subsequent investigations have identified ISX-9 as an activator of the canonical Wnt/beta-catenin signaling pathway through promotion of the LRP6-Axin1 interaction [3], and as a ligand of the proton-sensing G protein-coupled receptor GPR68 (OGR1), which is expressed in hippocampal type 1 neural stem cells and couples extracellular pH sensing to neurogenic signaling [4].

The *in vivo* pharmacology of ISX-9 is dominated by its proneurogenic activity in the adult hippocampal dentate gyrus. Systemic administration at 20 mg/kg intraperitoneally in mice enhances subgranular zone neuroblast proliferation and differentiation, increases dendritic arborization of newly generated granule cell neurons, and improves hippocampus-dependent spatial memory in the Morris water maze [2]. These effects require MEF2 isoform expression in neural stem cells, as demonstrated by transgenic-mediated inducible knockout of *Mef2a/c/d* in the Petrik et al. (2012) study [2].

Beyond hippocampal neurogenesis, ISX-9 has demonstrated activity in preclinical models of methamphetamine addiction (blocking abstinence-induced neurogenesis that drives context-dependent relapse) [5]; endocrine progenitor specification in intestinal organoids [6]; Wnt-dependent hair follicle regeneration [3]; and neuroprotection in the 5xFAD Alzheimer's disease model [7]. The compound has not entered human clinical development. No human pharmacokinetic, efficacy, or safety data exist. ISX-9 is positioned as a research tool compound with broad utility in stem cell biology, regenerative medicine, and neuroscience investigation. The cell-type-specific effects (proneurogenic for NSPCs but cytotoxic to oligodendrocyte precursor cells) [8] and the absence of human translation data are the principal limitations on its current research-clinical positioning.

3. Discovery and Development History

3.1 Origin

ISX-9 was identified in a high-throughput phenotypic screen conducted at the University of Texas Southwestern Medical Center by Schneider, Bhatt, Li, Gao, and colleagues, reported in *Nature Chemical Biology* in July 2008 under the title "Small-molecule activation of neuronal cell fate" [1]. The screen employed adult rat hippocampal neural stem/progenitor cells cultured under proliferative (growth factor-maintained) conditions and assayed for compounds that could trigger neuronal differentiation as measured by expression of neuronal markers including NeuroD1 and beta-III tubulin. A library of isoxazole-based small molecules was tested, and ISX-9 (the ninth isoxazole derivative in the screen series) emerged as the most potent and selective hit, producing robust neuronal differentiation at low-micromolar concentrations while blocking gliogenesis (astrocyte differentiation) in the same cultures.

The screen was designed as a phenotypic, target-agnostic approach: the assay endpoint was neuronal cell fate conversion rather than binding to a pre-specified molecular target. This design strategy was deliberate, reflecting the investigators' hypothesis that the complexity of neuronal differentiation programs would be better captured by phenotypic than by target-based screening. The isoxazole chemotype was selected for the library on the basis of its drug-like properties, synthetic accessibility, and the diversity of substitution patterns achievable at the 3- and 5-positions of the isoxazole ring.

3.2 Mechanistic characterization

The Schneider et al. (2008) report established the initial mechanistic framework: ISX-9 triggered calcium influx in neural stem cells, activating calcium/calmodulin-dependent protein kinase (CaMK) signaling, which phosphorylated HDAC5 and promoted its nuclear export. The consequent de-repression of MEF2-dependent transcription drove expression of neuronal lineage genes including NeuroD1 [1]. This calcium-to-MEF2-to-NeuroD1 axis was the first characterized mechanism of ISX-9 action and remains the best-validated pathway for its proneurogenic effects.

3.3 In vivo validation

The Petrik et al. (2012) study in *The FASEB Journal* provided the first in vivo demonstration that ISX-9 crosses the blood-brain barrier and enhances adult hippocampal neurogenesis [2]. The study administered ISX-9 at 20 mg/kg intraperitoneally to adult C57BL/6 mice and demonstrated enhanced proliferation and neuronal commitment of subgranular zone progenitors, increased dendritic complexity of adult-born neurons, and improved spatial memory in the Morris water maze. Critically, the study employed transgenic mice with inducible knockout of *Mef2a/c/d* in nestin-expressing neural stem cells and their progeny, confirming that the ISX-9 neurogenic effect requires MEF2 transcription factor activity in the target cell population.

3.4 Target identification

A chemical biology and target identification study by Russell et al. tracked the mechanism of action of ISX-9 and related proneurogenic isoxazoles to GPR68 (OGR1), a proton-sensing G protein-coupled receptor [4]. GPR68 is a member of the proton-sensing GPCR family that is activated by extracellular acidification (pH below approximately 7.4) and signals through Gq/11-phospholipase C pathways. The receptor is expressed in hippocampal neural stem cells and in peri-infarct border zone tissue following myocardial ischemia. ISX-9 was characterized as pharmacologically activating GPR68-dependent gene expression programs, providing a molecular receptor target for the compound and linking its proneurogenic activity to extracellular pH sensing in the neurogenic niche. The GPR68 target identification also extended the potential applications of ISX-9 to cardiac tissue, where GPR68 was validated as a previously unrecognized regulator of myocardial cellular responses to tissue acidosis [4].

3.5 Expansion of the research literature

From 2015 to 2026, the ISX-9 research literature expanded substantially beyond hippocampal neurogenesis. Major directions include: (a) addiction neuroscience, with the Mandyam laboratory at the Scripps Research Institute demonstrating that ISX-9 blocks methamphetamine relapse in a rat model by modulating abstinence-induced neurogenesis [5]; (b) endocrine cell biology, with Lalioti et al. (2020) demonstrating that ISX-9 manipulates endocrine progenitor fate in mouse and human intestinal organoids [6]; (c) hair follicle biology, with Sayed et al. (2023) characterizing

ISX-9 as a Wnt/beta-catenin pathway activator that promotes hair regrowth through Axin1 targeting [3]; (d) cell-type specificity, with Koh et al. (2015) demonstrating differential and sometimes adverse effects on non-neuronal progenitor populations [8]; and (e) Alzheimer's disease, with a 2026 study demonstrating neuroprotection and cognitive rescue in 5xFAD transgenic mice through Wnt/beta-catenin pathway activation [7].

3.6 Clinical development status

ISX-9 has not entered human clinical trials. No investigational new drug (IND) application or clinical trial authorization has been filed for the compound. The compound remains an academic research tool. No pharmaceutical company has advanced ISX-9 into formal preclinical development for any indication. The barriers to clinical translation include the absence of formal pharmacokinetic characterization in species suitable for human dose projection, the absence of formal toxicology (GLP-compliant repeat-dose studies, genetic toxicology, reproductive toxicology), and the cell-type-specific toxicity profile (oligodendrocyte precursor cell cytotoxicity) that would require careful evaluation in any central nervous system indication [8].

4. Mechanism of Action

ISX-9 operates through at least three characterized signaling mechanisms that converge on neuronal gene expression programs. The mechanisms are not mutually exclusive; they likely operate in parallel and in a cell-type-dependent manner.

4.1 Calcium-dependent MEF2 de-repression

The primary characterized mechanism of ISX-9, established in the original Schneider et al. (2008) report and validated in vivo by Petrik et al. (2012), is a calcium-dependent transcriptional de-repression pathway [1, 2].

ISX-9 induces intracellular calcium influx through two channel systems: voltage-gated calcium channels (L-type and possibly T-type) and NMDA-type glutamate receptors. The calcium influx activates calcium/calmodulin-dependent protein kinase II (CaMKII). Activated CaMKII phosphorylates histone deacetylase 5 (HDAC5) at serines 259 and 498, creating 14-3-3 protein binding sites that promote nuclear export of HDAC5. In the nucleus, HDAC5 functions as a corepressor of the myocyte-enhancer factor 2 (MEF2) family of transcription factors. Its nuclear export de-represses MEF2, allowing MEF2 to activate transcription of neuronal lineage genes, most notably the basic helix-loop-helix transcription factor NeuroD1 [1, 2].

NeuroD1 is a master regulator of neuronal differentiation. Its expression is necessary and, in some contexts, sufficient for neuronal commitment of multipotent progenitor cells. The ISX-9-induced upregulation of NeuroD1 expression drives downstream expression of neuronal structural genes (beta-III tubulin, MAP2, NeuN) and suppresses glial lineage commitment (GFAP, Olig2) in the same progenitor population.

The MEF2 requirement was formally demonstrated in the Petrik et al. (2012) study using transgenic mice carrying a tamoxifen-inducible Cre-mediated knock-out of *Mef2a*, *Mef2c*, and *Mef2d* under the nestin promoter [2]. In these animals, ISX-9 failed to enhance hippocampal neurogenesis, confirming that MEF2 activity in neural stem cells is required for the proneurogenic effect. This genetic validation places the calcium-CaMKII-HDAC5-MEF2-NeuroD1 axis at the center of the ISX-9 mechanism.

4.2 Wnt/beta-catenin pathway activation

ISX-9 activates the canonical Wnt/beta-catenin signaling pathway through a mechanism characterized by Sayed et al. (2023) in the British Journal of Pharmacology [3]. ISX-9 promotes the physical association between low-density lipoprotein receptor-related protein 6 (LRP6), the Wnt co-receptor, and Axin1, a scaffold protein of the beta-catenin destruction complex. This association, which mimics the early events of Wnt ligand binding, leads to phosphorylation of LRP6, sequestration of Axin1 away from the destruction complex, and consequent stabilization of cytoplasmic beta-catenin. Stabilized beta-catenin translocates to the nucleus where it interacts with TCF/LEF transcription factors to activate Wnt target gene expression, including genes involved in cell proliferation (cyclin D1, c-Myc) and stemness (Lgr5, Axin2) [3].

The Wnt/beta-catenin mechanism is particularly relevant to two ISX-9 applications: hair follicle regeneration (where Wnt signaling is the master regulator of hair follicle cycling from telogen to anagen phase) and Alzheimer's disease neuroprotection (where defective Wnt signaling has been implicated in disease pathogenesis and beta-catenin stabilization is neuroprotective against amyloid-beta-induced toxicity) [3, 7].

The relationship between the calcium-MEF2 pathway and the Wnt pathway is incompletely characterized. The two pathways may operate independently on different downstream gene programs, or they may intersect through calcium-dependent regulation of Wnt signaling components. Both pathways converge on NeuroD1 expression, which is a known Wnt target gene in the developing nervous system.

4.3 GPR68 agonism

ISX-9 was identified as a ligand of GPR68 (OGR1, ovarian cancer G protein-coupled receptor 1), a proton-sensing GPCR that is activated by extracellular acidification below pH 7.4 [4]. GPR68 signals through Gq/11-coupled phospholipase C activation, generating inositol trisphosphate (IP3) and diacylglycerol (DAG), which in turn mobilize intracellular calcium stores and activate protein kinase C. The receptor is expressed in hippocampal type 1 neural stem cells and in cardiac tissue, particularly in peri-infarct border zones following ischemia.

The GPR68 target identification provides a receptor-level explanation for the calcium influx that initiates the MEF2 pathway: ISX-9 may activate GPR68 on neural stem cells, triggering Gq/11-dependent calcium mobilization that is supplemented by secondary calcium entry through voltage-gated channels and NMDA receptors. This model links the proneurogenic activity of ISX-9 to extracellular pH sensing in the stem cell niche, a physiologically meaningful context given that neurogenic niches in the adult brain are characterized by local pH fluctuations associated with neural activity, metabolic demand, and vascular dynamics [4].

4.4 Composite pharmacology

The composite pharmacology of ISX-9 at research concentrations (typically 10 to 20 micromolar in vitro, 20 mg/kg intraperitoneally in vivo) therefore involves: (a) GPR68-mediated initial calcium signaling; (b) calcium influx through voltage-gated calcium channels and NMDA receptors; (c) CaMKII activation leading to HDAC5 nuclear export and MEF2 de-repression; (d) Wnt/beta-catenin pathway activation through LRP6-Axin1 association; and (e) convergent upregulation of NeuroD1 and other neuronal lineage transcription factors. The relative contribution of each pathway likely varies by cell type, extracellular pH, and the expression profile of the relevant receptors and signaling components in the target tissue.

5. Pharmacokinetics and Routes of Administration

5.1 Absorption and blood-brain barrier penetration

Formal pharmacokinetic characterization of ISX-9 in any species has not been published. The available evidence for in vivo disposition derives from the Petrik et al. (2012) demonstration of central nervous system activity following intraperitoneal administration [2] and from the general physicochemical profile of the compound.

ISX-9 crosses the blood-brain barrier. This was established functionally by the Petrik et al. (2012) study, which demonstrated enhanced hippocampal dentate gyrus neurogenesis and improved Morris water maze performance following systemic (intraperitoneal) ISX-9 administration at 20 mg/kg in adult mice [2]. The blood-brain barrier penetration is consistent with the compound's physicochemical properties: molecular weight 234.28 (below the 450 threshold for CNS-penetrant compounds), moderate lipophilicity, absence of formal charge at physiological pH, low polar surface area, and low hydrogen bond donor count.

5.2 Distribution

No formal distribution studies (tissue partitioning, plasma protein binding, volume of distribution) have been published. The compound is inferred to distribute to the central nervous system on the basis of functional pharmacology. Distribution to peripheral tissues is probable given systemic administration; the effects on intestinal endocrine progenitors observed by Lalioti et al. (2020) in ex vivo organoids [6] suggest that peripheral tissue concentrations at effective in vitro concentrations (2 to 80 micromolar) are pharmacologically relevant.

5.3 Metabolism

Metabolic pathways for ISX-9 have not been characterized. The isoxazole ring, thiophene ring, and cyclopropylcarboxamide are all susceptible to hepatic cytochrome P450-mediated oxidation. The thiophene 5-position is a plausible site for S-oxidation or epoxidation; thiophene-containing compounds are known substrates for

CYP-mediated bioactivation, which in some cases produces reactive metabolites. No data on ISX-9 metabolite identity, metabolic stability, or CYP isoform selectivity have been published.

5.4 Elimination

Elimination pathways have not been characterized. No plasma half-life, clearance, or urinary/biliary excretion data are available.

5.5 Routes of administration

Intraperitoneal (research standard): The principal *in vivo* route in published studies is intraperitoneal injection in mice and rats, typically at 20 mg/kg [2, 5]. Vehicle systems include DMSO/saline mixtures and DMSO/polyethylene glycol formulations.

Topical: Sayed et al. (2023) administered ISX-9 topically to the dorsal skin of C57BL/6J mice for hair regrowth studies [3]. A thermoresponsive nanoparticle formulation for topical delivery was subsequently developed and characterized [10].

In vitro: The standard *in vitro* concentration range is 2.5 to 50 micromolar, with neurogenic effects typically observed at 10 to 20 micromolar and dose-dependent effects across this range [1, 2, 8]. Stock solutions are prepared in DMSO at 10 to 50 mM and diluted into culture media immediately before use.

Oral: No oral administration studies have been published. Oral bioavailability is unknown.

5.6 Special populations

No data exist for any special population. The compound has been studied exclusively in adult rodents (mice and rats) and in *ex vivo* human and mouse tissue models. No pediatric, geriatric, hepatic impairment, or renal impairment pharmacokinetic data are available.

6. Preclinical Pharmacology

6.1 Hippocampal neurogenesis and cognitive enhancement

The Petrik et al. (2012) study is the principal in vivo pharmacology report [2]. Adult C57BL/6 mice received ISX-9 at 20 mg/kg intraperitoneally, and the effects on hippocampal dentate gyrus neurogenesis were assessed by bromodeoxyuridine (BrdU) incorporation, doublecortin (DCX) immunohistochemistry, and confocal morphological analysis of adult-born neurons. ISX-9 treatment produced: (a) increased proliferation of subgranular zone progenitors; (b) increased proportion of BrdU-positive cells expressing neuronal markers (NeuN, DCX), indicating enhanced neuronal commitment; (c) increased dendritic arborization and spine density of adult-born granule cell neurons in the dentate gyrus; and (d) improved spatial memory performance in the Morris water maze, as measured by reduced escape latency and increased time in the target quadrant during probe trials.

The neurogenic effects were abolished in transgenic mice with inducible knock-out of Mef2a/c/d in nestin-expressing neural stem cells, confirming MEF2 dependence [2]. Importantly, ISX-9 did not increase overall locomotor activity or alter vascular density in the hippocampus, ruling out non-specific confounding factors for the behavioral improvement.

Ramirez-Rodriguez et al. (2016) extended these findings in the rat dentate gyrus, demonstrating that ISX-9 potentiates cell proliferation and neuronal commitment in a concentration-dependent manner consistent with the mouse data [11].

6.2 Methamphetamine relapse prevention

Mandyam and colleagues (2017) reported in *Molecular Psychiatry* that ISX-9 protects against methamphetamine relapse in a rat self-administration model [5]. The study was based on the observation that forced abstinence from methamphetamine self-administration triggers aberrant neurogenesis in the dentate gyrus, producing new granule cell neurons that strengthen drug-associated contextual memories and drive compulsive-like drug seeking upon re-exposure to the drug-associated context. Systemic ISX-9 treatment during the abstinence period blocked this context-driven reinstatement of methamphetamine seeking. The mechanism was at-

tributed to ISX-9's modulation of the timing and fate of abstinence-induced neurogenesis, effectively preventing the maturation of new neurons into circuits that encode drug-context associations.

This application represents an inversion of the conventional proneurogenic framing of ISX-9: rather than promoting beneficial neurogenesis, the compound modulates the quality and circuit integration of newly generated neurons to prevent maladaptive memory formation. The finding highlights the complexity of neurogenesis modulation as a therapeutic strategy and the context-dependent nature of ISX-9's effects.

6.3 Alzheimer's disease neuroprotection

A 2026 study published in *Alzheimer's Research and Therapy* demonstrated that ISX-9 exerts neuroprotective effects in the 5xFAD transgenic mouse model of Alzheimer's disease through activation of the Wnt/beta-catenin signaling pathway [7]. The 5xFAD model carries five familial Alzheimer's disease mutations in amyloid precursor protein and presenilin 1 and develops aggressive amyloid plaque deposition, neuronal loss, and cognitive deficits. ISX-9 treatment: (a) increased viability and proliferation of hippocampal neurons; (b) ameliorated hippocampal neuronal damage; (c) improved learning and memory performance in behavioral testing, with escape latency significantly reduced and the platform index restored to near wild-type levels; and (d) activated Wnt/beta-catenin signaling by promoting LRP6-Axin1 association in hippocampal tissue [7].

This study extends the therapeutic relevance of ISX-9 beyond neurogenesis *per se* to neuroprotection in a neurodegenerative disease context, where defective Wnt/beta-catenin signaling is increasingly recognized as a contributor to amyloid-beta-induced neuronal death and synaptic dysfunction.

6.4 Hair follicle regeneration

Sayed et al. (2023) characterized ISX-9 as a promoter of hair regrowth in C57BL/6J mice [3]. Topical application of ISX-9 induced transition of hair follicles from telogen (resting phase) to anagen (growth phase) via activation of the Wnt/beta-catenin pathway. The mechanism was characterized at the molecular level: ISX-9 promoted the physical association between LRP6 and Axin1 (targeting the N-terminal region of Axin1), resulting in beta-catenin stabilization, nuclear translocation, and upreg-

ulation of Wnt target genes including cyclin D1, c-Myc, Lgr5, and Axin2. A subsequent study developed ISX-9-loaded thermoresponsive nanoparticles for sustained topical delivery, demonstrating enhanced hair follicle regrowth compared to ISX-9 in conventional vehicle [10].

6.5 Endocrine progenitor specification

Lalioti et al. (2020) demonstrated that ISX-9 manipulates endocrine progenitor fate in mouse and human intestinal organoids [6]. In this system, ISX-9 increased the number of neurogenin 3 (Ngn3)-positive endocrine progenitor cells and upregulated NeuroD1 and Pax4, transcription factors involved in enteroendocrine cell (EEC) specification. Single-cell RNA sequencing revealed that ISX-9 treatment drove enteroendocrine progenitors toward specific lineages (enterochromaffin cells, I-cells) in a conserved manner between mouse and human organoids. The finding exploits the shared developmental logic between neuronal and endocrine differentiation programs, both of which depend on the Ngn3-NeuroD1 transcription factor cascade that ISX-9 activates [6].

ISX-9 has also been used as a tool compound in studies of pancreatic beta-cell differentiation, where isoxazole compounds alter metabolite profiles and gene expression to promote neuroendocrine phenotypes [12].

6.6 Differential effects on progenitor populations

Koh et al. (2015) characterized the effects of ISX-9 on three distinct progenitor populations derived from the adult central nervous system: neural stem/progenitor cells (NSPCs), oligodendrocyte precursor cells (OPCs), and endothelial progenitor cells (EPCs) [8]. The effects were strikingly cell-type specific:

- NSPCs: ISX-9 slightly increased cell number and effectively induced neuronal differentiation, consistent with prior reports.
- OPCs: ISX-9 significantly decreased OPC number in a concentration-dependent manner, indicating cytotoxicity to this progenitor population.
- EPCs: ISX-9 did not affect cell number but significantly inhibited tube formation (angiogenesis) in a Matrigel assay of outgrowth endothelial cells derived from EPCs.

These differential effects have important implications for in vivo applications, particularly in central nervous system injury models (stroke, traumatic brain injury, demyelinating disease) where neurogenesis, oligodendrogenesis, and angiogenesis must all proceed for functional recovery. ISX-9's cytotoxicity to OPCs and anti-angiogenic activity could compromise remyelination and revascularization even while promoting neurogenesis. Investigators should consider these cell-type-specific effects when designing combination studies or when interpreting in vivo outcomes in injury models.

7. Clinical Evidence Base

No clinical evidence exists for ISX-9. The compound has not been administered to humans in any context (healthy volunteer, patient, compassionate use). No investigational new drug application, clinical trial authorization, or institutional review board protocol for human administration has been filed or published.

The absence of clinical data reflects the compound's positioning as an academic research tool rather than a pharmaceutical development candidate. The principal barriers to clinical translation are: (a) absence of GLP-compliant toxicology studies; (b) absence of formal pharmacokinetic characterization suitable for human dose projection; (c) the cell-type-specific toxicity profile (OPC cytotoxicity, anti-angiogenic activity) that would require careful safety evaluation; (d) the thiophene ring, which raises potential concerns for reactive metabolite formation through CYP-mediated S-oxidation; and (e) the availability of alternative neurogenesis-promoting compounds (notably NSI-189) that have advanced further toward clinical development.

Investigators considering ISX-9 for translational research should recognize that any clinical application would require a complete preclinical development program from first principles, including absorption, distribution, metabolism, and excretion (ADME) characterization; dose-ranging toxicology in at least two species; genetic toxicology; and reproductive toxicology.

8. Sourcing and Quality Verification

ISX-9 is commercially available from multiple research chemical and biochemical suppliers at research grade (greater than 98 percent purity by HPLC). The compound is not available at pharmaceutical grade, as it has not entered pharmaceutical development and is not subject to any pharmacopoeial monograph.

Principal suppliers: Tocris Bioscience (catalog 4439); Cayman Chemical (catalog 16165); Selleck Chemicals (catalog S6625); MedChemExpress (catalog HY-12585); Sigma-Aldrich/MilliporeSigma (various catalog numbers); STEMCELL Technologies (catalog 73202); Enzo Life Sciences; AG Scientific; AbMole BioScience; BioCrick; TargetMol; Probecchem Biochemicals. Supply quantities range from 5 mg to 100 mg per vial at standard catalog offerings, with larger quantities available on custom order.

Pricing: Moderate for a research tool compound. Typical pricing is in the range of \$40 to \$150 per 10 mg depending on supplier and lot size.

Quality verification: Investigators should confirm compound identity and purity on each lot through:

- High-performance liquid chromatography area-percent purity (target greater than 98 percent)
- Mass spectrometry confirmation of molecular weight (234.05 plus or minus 0.01 for the protonated molecular ion $[M+H]^+$, m/z 235.05)
- Proton nuclear magnetic resonance spectroscopy for structural confirmation (characteristic signals for the cyclopropyl protons, the isoxazole ring proton, and the thiophene ring protons)
- Functional bioassay confirmation if the intended application is quantitative (e.g., neuronal differentiation assay in adult hippocampal NSPCs with positive control comparison)

The ISX-9 research chemical market is well established with multiple independent suppliers; counterfeit material risk is low. Lot-to-lot variability in potency is possible and functional testing on receipt is advisable for quantitative studies.

9. Reconstitution and Handling

ISX-9 is supplied as a solid powder (off-white to pale yellow). The compound is sparingly soluble in aqueous media and is reconstituted in dimethyl sulfoxide (DMSO) for laboratory use.

Stock solution preparation: Dissolve ISX-9 in anhydrous DMSO at a concentration of 10 to 50 mM (2.34 to 11.7 mg/mL). Vortex or sonicate briefly to ensure complete dissolution. The resulting solution should be clear and colorless to pale yellow.

Working solution preparation: Dilute the DMSO stock solution into the final experimental medium (cell culture medium, physiological saline, or vehicle) immediately before use. Final DMSO concentration in biological assays should be maintained below 0.1 to 0.5 percent (v/v) to avoid solvent-related cytotoxicity. For in vivo intraperitoneal injection, common vehicles include DMSO/saline (10 percent DMSO in sterile normal saline) and DMSO/polyethylene glycol 300/saline mixtures.

Storage: Store the dry solid at minus 20 degrees Celsius, protected from moisture. Aliquot DMSO stock solutions into single-use volumes and store at minus 20 degrees Celsius; avoid repeated freeze-thaw cycles. Stock solutions stored under these conditions are generally stable for at least 6 months based on supplier recommendations [9]. Aqueous working solutions should be prepared fresh and used within 24 hours.

Light sensitivity: The compound is not reported to be significantly light-sensitive, but protection from prolonged light exposure during storage and handling is prudent given the thiophene and isoxazole chromophores.

Handling precautions: ISX-9 is a bioactive research chemical with demonstrated effects on stem cell differentiation. Standard laboratory safety precautions for handling bioactive small molecules apply: work in a chemical fume hood or biological safety cabinet as appropriate; wear gloves, lab coat, and eye protection; avoid inhalation of dust or aerosols during weighing.

10. Stack Interactions and Combinations

ISX-9 has been used as a component of multi-compound research protocols and in combination with other signaling pathway modulators. The following interaction considerations are relevant for investigators designing combination studies.

Wnt pathway agonists (CHIR99021, lithium chloride, Wnt3a): ISX-9 activates the Wnt/beta-catenin pathway through LRP6-Axin1 association [3]. Combination with GSK-3beta inhibitors (CHIR99021, lithium chloride) or with recombinant Wnt ligands (Wnt3a) may produce additive or synergistic beta-catenin stabilization. The combination has been used in stem cell differentiation cocktails where robust Wnt activation is desired. Investigators should monitor for excessive proliferative signaling and potential oncogenic transformation in long-term culture.

Calcium channel modulators: ISX-9 induces calcium influx through voltage-gated calcium channels and NMDA receptors [1]. Calcium channel blockers (nifedipine, verapamil) or NMDA receptor antagonists (MK-801, memantine, AP5) would be expected to attenuate ISX-9-mediated neuronal differentiation by reducing the initial calcium signal. Conversely, calcium ionophores or NMDA receptor potentiators could amplify the signal. The Schneider et al. (2008) study confirmed that calcium chelation (BAPTA-AM) abolishes ISX-9's neurogenic activity [1].

HDAC inhibitors (valproic acid, vorinostat, trichostatin A): ISX-9 acts through HDAC5 nuclear export [1]. Pharmacological HDAC inhibition by pan-HDAC inhibitors would bypass the HDAC5-specific mechanism and potentially produce broader chromatin remodeling effects. The interaction could be additive for neuronal gene activation but may introduce off-target effects through inhibition of HDAC isoforms not engaged by ISX-9 alone. Valproic acid is commonly used in small molecule reprogramming cocktails alongside isoxazole compounds.

Growth factors (EGF, FGF-2, BDNF): ISX-9 was originally characterized in neural stem cell cultures maintained with EGF and FGF-2 [1]. Withdrawal of these mitogenic growth factors in combination with ISX-9 treatment drives differentiation.

BDNF supplementation may enhance the survival and maturation of ISX-9-differentiated neurons. No adverse pharmacological interaction between ISX-9 and standard neurotrophic growth factors has been reported.

Notch pathway inhibitors (DAPT, gamma-secretase inhibitors): Notch inhibition promotes neuronal differentiation from neural progenitors by de-repressing proneural genes. Combination with ISX-9 may produce additive proneurogenic effects through convergent activation of NeuroD1 expression. This combination is used in some intestinal organoid differentiation protocols to drive enteroendocrine lineage specification [6].

CYP substrates and inhibitors: In the absence of metabolic data for ISX-9, potential CYP-mediated drug-drug interactions cannot be predicted. Investigators using ISX-9 in vivo in combination with other compounds should consider the possibility of metabolic interactions, particularly with known CYP3A4 and CYP2D6 substrates.

11. Adverse Events and Safety Signal

11.1 In vivo safety profile

Formal toxicology studies for ISX-9 have not been conducted under Good Laboratory Practice (GLP) conditions. The available safety data derive from the in vivo efficacy studies described above.

In the hair regrowth study (Sayed et al. 2023), ISX-9-treated mice showed no evidence of hepatotoxicity or nephrotoxicity as assessed by serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine (CREA), and blood urea nitrogen (BUN) levels [3]. Histological examination of major organs (heart, lung, spleen, liver, and kidney) did not reveal any evident toxicity. Hematological parameters (white blood cells, red blood cells, platelets, hemoglobin, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, hematocrit, mean corpuscular volume) were within normal ranges in ISX-9-treated groups.

The Petrik et al. (2012) study reported no overt adverse effects at 20 mg/kg intraperitoneally in mice and specifically noted no changes in locomotor activity or overall animal behavior [2].

11.2 Cell-type-specific toxicity

The Koh et al. (2015) study identified a significant safety concern: ISX-9 is cytotoxic to oligodendrocyte precursor cells (OPCs) in a concentration-dependent manner and inhibits angiogenic tube formation in endothelial progenitor cells [8]. These effects were observed at concentrations comparable to those producing proneurogenic activity in neural stem/progenitor cells (10 to 20 micromolar). The OPC cytotoxicity raises concerns for any central nervous system application where myelination or remyelination is important for functional recovery. The anti-angiogenic activity raises concerns for applications in ischemic or traumatic injury where revascularization is required.

11.3 Thiophene-related concerns

The thiophene ring in ISX-9 is a structural alert for potential bioactivation through cytochrome P450-mediated S-oxidation, which can produce reactive thiophene epoxide or thiophene S-oxide intermediates. These reactive metabolites can form covalent adducts with cellular macromolecules (proteins, DNA) and have been implicated in idiosyncratic hepatotoxicity with other thiophene-containing drugs (tienilic acid, suprofen). No data on ISX-9 reactive metabolite formation have been published, and the clinical relevance of this structural alert is unknown. However, investigators designing chronic dosing protocols should be aware of this theoretical concern.

11.4 Reproductive and developmental toxicity

No reproductive or developmental toxicity data exist for ISX-9. Given the compound's potent effects on stem cell differentiation and Wnt/beta-catenin signaling (a pathway with critical roles in embryonic development), teratogenic potential cannot be excluded. The compound should not be used in pregnant animals without specific risk assessment.

11.5 Mutagenicity and carcinogenicity

No mutagenicity or carcinogenicity data exist for ISX-9. The activation of Wnt/beta-catenin signaling and the promotion of cell proliferation are theoretical concerns for oncogenic transformation in chronic exposure, given the well-characterized role of aberrant Wnt activation in colorectal and other cancers.

12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five neurogenesis-promoting small molecules against ISX-9, evaluated on five standards: novelty of mechanism, effect size in preclinical models, clinical translation status, side-effect profile, and overall validation. The five comparators were selected as the principal small molecules with published neurogenesis-promoting activity and with varying degrees of clinical or preclinical development.

12.1 P7C3

Mechanism: P7C3 (3,6-dibromo- α -(1-piperazinylmethyl)-9H-carbazol-9-ethanol) is an aminopropyl carbazole neuroprotective agent identified through an *in vivo* phenotypic screen for compounds that enhance the net magnitude of adult hippocampal neurogenesis [13]. The mechanism was subsequently characterized as activation of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the NAD salvage pathway. P7C3 enhances neurogenesis by promoting survival of immature neurons rather than by inducing differentiation, a mechanistically distinct approach from ISX-9's pro-differentiation activity.

Novelty: Moderate to high. The NAMPT-mediated neuroprotective mechanism is distinct from conventional neurotrophin or kinase signaling approaches and from the calcium-MEF2 mechanism of ISX-9.

Effect size: Substantial in preclinical models. P7C3 and its derivative P7C3-A20 have demonstrated neuroprotective efficacy in models of aging, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, and ischemic stroke, with effect sizes in hippocampal neurogenesis enhancement comparable to or exceeding ISX-9 at optimized doses [13, 14]. P7C3-A20 has been shown to enhance hippocampal neurogenesis in aged nonhuman primates (rhesus macaques), a level of preclinical validation not achieved by ISX-9 [14].

Clinical translation: No clinical trials completed. The compound is in preclinical development. Research-grade P7C3 and derivatives are commercially available.

Side-effect profile: Favorable in preclinical studies. No material toxicity signals reported at effective doses in rodents or nonhuman primates.

Overall validation: Moderate to high. Extensive preclinical literature across multiple disease models and species, including nonhuman primates. The NAMPT mechanism is well characterized and independently validated.

Comparison to ISX-9: P7C3 and ISX-9 promote adult neurogenesis through fundamentally different mechanisms: P7C3 promotes survival of newly born neurons (neuroprotection), while ISX-9 promotes differentiation of neural stem cells into neurons (pro-differentiation). The two compounds are mechanistically complementary and could potentially be combined to simultaneously increase neuronal differentiation and survival. P7C3 has broader species validation (including nonhuman primates) and a larger preclinical disease model portfolio. ISX-9 has the advantage of multi-pathway engagement (calcium-MEF2, Wnt, GPR68) and broader application beyond neurogenesis (endocrine differentiation, hair follicle regeneration).

12.2 NSI-189

Mechanism: NSI-189 (amdiglurax phosphate; (4S,5R)-2-[6-(4-fluorophenyl)pyridin-3-yl]-5-methyl-1-(pyridin-3-ylmethyl)-4,5-dihydro-1H-pyrazole-4-carboxamide phosphate) is a neurogenic compound that stimulates hippocampal neurogenesis through a mechanism that is incompletely characterized but involves upregulation of brain-derived neurotrophic factor (BDNF) and stem cell factor (SCF) [15]. The molecular target has not been definitively identified.

Novelty: Moderate. The phenotypic neurogenic activity is well established, but the molecular mechanism remains incompletely characterized.

Effect size: Phase 2 clinical trial in major depressive disorder (220 subjects, 12-week treatment) demonstrated approximately 2.4 percent hippocampal volume increase versus placebo (measured by MRI), a biologically meaningful structural change [16]. However, the primary clinical endpoint (MADRS depression score reduction) did not reach statistical significance at either the 40 mg or 80 mg daily dose. Positive signals on secondary cognitive endpoints were observed.

Clinical translation: Most advanced among the comparators. NSI-189 completed a Phase 2 randomized double-blind placebo-controlled trial in major depressive disorder [16]. The compound was safe and well tolerated with no serious adverse

events. Despite the negative primary endpoint, the hippocampal volume and cognitive findings supported continued development. The compound has been licensed for further clinical development.

Side-effect profile: Favorable. No serious adverse events in Phase 2. Common adverse events were mild and comparable to placebo in frequency.

Overall validation: Moderate. The hippocampal volume finding is the strongest structural biomarker evidence for any neurogenesis-promoting compound in human subjects. The negative primary clinical endpoint tempers the overall validation.

Comparison to ISX-9: NSI-189 is substantially more advanced in clinical translation than ISX-9, with completed Phase 2 human data. ISX-9 has a better-characterized molecular mechanism (calcium-MEF2-NeuroD1 axis, Wnt pathway, GPR68) compared to NSI-189's undefined target. ISX-9 has broader preclinical application diversity (neurogenesis, endocrine specification, hair regrowth, addiction). For investigators seeking a neurogenesis-promoting compound with human safety data, NSI-189 is the current leader. For investigators seeking a mechanistically characterized tool compound with multi-pathway engagement, ISX-9 offers advantages.

12.3 7,8-Dihydroxyflavone (7,8-DHF)

Mechanism: 7,8-DHF is a naturally occurring flavone that acts as a small molecule agonist of tropomyosin receptor kinase B (TrkB), the high-affinity receptor for brain-derived neurotrophic factor (BDNF) [17]. TrkB activation promotes neuronal survival, differentiation, synaptic plasticity, and adult hippocampal neurogenesis through Ras-MAPK, PI3K-Akt, and PLCgamma signaling cascades.

Novelty: Moderate. TrkB agonism is a well-established neurotrophic mechanism. The novelty lies in a small molecule mimicking the activity of the large protein BDNF.

Effect size: Moderate in preclinical models. 7,8-DHF promotes hippocampal neurogenesis, enhances long-term potentiation, and improves cognitive performance in rodent models of aging, Alzheimer's disease, depression, and traumatic brain injury. Effect sizes are generally modest and consistent across studies.

Clinical translation: No clinical trials completed for neurogenesis indications. The compound is available as a dietary supplement in some markets, but without regulatory approval for any therapeutic indication.

Side-effect profile: Generally favorable in preclinical studies. The flavone scaffold is considered safe at moderate doses. Concerns exist regarding bioavailability (low oral bioavailability in rodents) and selectivity (potential off-target activity at other kinase receptors and at estrogen receptors).

Overall validation: Moderate. Extensive preclinical literature, but limited by bioavailability challenges and absence of human clinical data for neurogenesis endpoints.

Comparison to ISX-9: 7,8-DHF and ISX-9 promote neurogenesis through different pathways: TrkB/BDNF signaling versus calcium-MEF2/Wnt/GPR68 signaling. The two mechanisms are complementary and non-overlapping at the receptor level. ISX-9 has the advantage of demonstrated blood-brain barrier penetration from systemic administration, while 7,8-DHF has known bioavailability limitations. ISX-9 has broader application diversity beyond neurogenesis, while 7,8-DHF benefits from the extensive BDNF/TrkB validation literature.

12.4 CHIR99021

Mechanism: CHIR99021 is a potent and selective inhibitor of glycogen synthase kinase 3 (GSK-3alpha and GSK-3beta), with IC50 values of 10 nM (GSK-3alpha) and 6.7 nM (GSK-3beta) [18]. GSK-3 inhibition stabilizes beta-catenin by preventing its phosphorylation-dependent ubiquitination and proteasomal degradation, thereby activating canonical Wnt/beta-catenin signaling. The compound is widely used as a Wnt pathway activator in stem cell biology.

Novelty: Low. GSK-3 inhibition is a well-established and widely used mechanism for Wnt pathway activation.

Effect size: CHIR99021 is highly effective at activating Wnt/beta-catenin signaling and is a standard component of many directed differentiation protocols for pluripotent stem cells (neural, cardiac, hepatic lineages). Its effects on adult hippocampal neurogenesis in vivo are less extensively characterized than ISX-9 or P7C3.

Clinical translation: CHIR99021 itself has not entered clinical trials. The compound is a research tool. However, GSK-3 inhibitors as a class (lithium, tideglusib) have clinical data for neuropsychiatric and neurodegenerative indications.

Side-effect profile: GSK-3 inhibition affects multiple signaling pathways beyond Wnt (glycogen metabolism, insulin signaling, tau phosphorylation, NF-kappaB), creating a broad pharmacological footprint with potential for off-target effects. Chronic Wnt pathway activation raises oncogenic transformation concerns.

Overall validation: High as a research tool for Wnt pathway activation. Low to moderate as a neurogenesis-promoting compound for in vivo applications due to the broad target profile.

Comparison to ISX-9: Both ISX-9 and CHIR99021 activate Wnt/beta-catenin signaling, but through different mechanisms: ISX-9 promotes LRP6-Axin1 association at the receptor level [3], while CHIR99021 inhibits GSK-3 at the destruction complex level. ISX-9 has additional calcium-MEF2 and GPR68 mechanisms not shared by CHIR99021. For Wnt-specific activation, CHIR99021 is more potent and selective. For multi-pathway neurogenic activation, ISX-9 provides a more complex pharmacological profile.

12.5 Dihexa

Mechanism: Dihexa (N-hexanoyl-L-tyrosyl-L-isoleucyl-(6)amino hexanoic amide) is a synthetic hexapeptide analog of angiotensin IV that acts as an agonist of hepatocyte growth factor (HGF) signaling through the c-Met receptor [19]. HGF/c-Met signaling promotes neuronal survival, neurite outgrowth, synaptogenesis, and hippocampal long-term potentiation.

Novelty: Moderate to high. The angiotensin IV/HGF/c-Met axis for cognitive enhancement is a non-obvious connection that emerged from receptor pharmacology studies at Washington State University.

Effect size: Large in preclinical models. Dihexa has been reported to be several orders of magnitude more potent than BDNF at promoting synaptogenesis in vitro and to restore cognitive function in aged rats at picomolar brain concentrations. Effect sizes in scopolamine-induced amnesia and aging models are among the largest reported for any neurogenic/nootropic compound in preclinical studies [19].

Clinical translation: No clinical trials completed. The compound has not entered formal pharmaceutical development. Dihexa is available through research chemical suppliers and through the gray-market peptide supply chain.

Side-effect profile: Minimally characterized. No formal toxicology. The HGF/c-Met axis has oncogenic potential (c-Met is a proto-oncogene with gain-of-function mutations in several cancers), raising theoretical long-term safety concerns for chronic administration.

Overall validation: Low to moderate. The preclinical effect sizes are impressive but derived from a limited number of studies from a single research group. Independent replication is limited. The oncogenic concerns around c-Met agonism are unresolved.

Comparison to ISX-9: Dihexa and ISX-9 operate through entirely different mechanisms (HGF/c-Met versus calcium-MEF2/Wnt/GPR68). Dihexa's reported preclinical potency is substantially higher than ISX-9's, but the evidence base is narrower and less independently validated. ISX-9 has a broader and more independently replicated research literature. ISX-9's mechanisms are better characterized at the molecular level. Both compounds lack human clinical data, but ISX-9 has a more complete preclinical safety characterization.

12.6 Comparator summary

The five comparator compounds occupy distinct positions in the neurogenesis-promoting landscape. **P7C3** is the most mechanistically distinct comparator (neuroprotective via NAMPT rather than pro-differentiation) and has the broadest species validation including nonhuman primates. **NSI-189** is the most clinically advanced, with completed Phase 2 human data demonstrating hippocampal volume increases, though the primary clinical endpoint was not met. **7,8-DHF** offers a BDNF-mimetic approach through TrkB agonism but is limited by bioavailability challenges. **CHIR99021** is the standard Wnt pathway activator but lacks the multi-pathway pharmacology and in vivo neurogenesis characterization of ISX-9. **Dihexa** reports the largest preclinical effect sizes through HGF/c-Met agonism but has the narrowest evidence base and unresolved oncogenic safety concerns.

ISX-9 occupies a unique position in this landscape as the most mechanistically characterized multi-pathway neurogenic agent. Its composite mechanism (calcium-MEF2-NeuroD1 plus Wnt/beta-catenin plus GPR68 agonism) provides a pharmaco-

logical profile not replicated by any single comparator. The in vivo validation of MEF2 dependence through genetic knockout is a level of mechanistic rigor not achieved by most comparators. The expanding application diversity (neurogenesis, addiction, endocrine specification, hair regrowth, Alzheimer's neuroprotection) distinguishes ISX-9 as a versatile research tool.

The principal limitations relative to the comparator panel are: (a) absence of human clinical data (inferior to NSI-189); (b) absence of nonhuman primate data (inferior to P7C3); (c) cell-type-specific toxicity (OPC cytotoxicity, anti-angiogenic activity) not reported for most comparators; and (d) absence of formal pharmacokinetic and toxicological characterization that would support clinical translation. Investigators selecting among these compounds should match the mechanism to the research question, consider the cell-type context, and recognize that ISX-9's strength is mechanistic clarity and application breadth rather than clinical maturity.

13. References

1. Schneider JW, Gao Z, Li S, et al. Small-molecule activation of neuronal cell fate. *Nat Chem Biol.* 2008;4(7):408-410.
2. Petrik D, Jiang Y, Biber SA, et al. Functional and mechanistic exploration of an adult neurogenesis-promoting small molecule. *FASEB J.* 2012;26(8):3148-3162.
3. Sayed KM, Mahmoud AA, Abdelsalam HM, et al. Isoxazole 9 (ISX9), a small molecule targeting Axin, activates Wnt/beta-catenin signalling and promotes hair regrowth. *Br J Pharmacol.* 2023;180(12):1609-1626.
4. Russell JL, Goetsch SC, Gaiano NR, et al. Regulated expression of pH sensing G Protein-coupled receptor-68 identified through chemical biology defines a new drug target for ischemic heart disease. *ACS Chem Biol.* 2012;7(6):1077-1083.
5. Galinato MH, Orio L, Mandyam CD. A synthetic small-molecule Isoxazole-9 protects against methamphetamine relapse. *Mol Psychiatry.* 2018;23(3):629-638.
6. Lalioti ME, Arnes L, Ochoa P, et al. ISX-9 manipulates endocrine progenitor fate revealing conserved intestinal lineages in mouse and human organoids. *Mol Metab.* 2020;36:100969.
7. ISX9 activates the Wnt/beta-catenin signaling pathway and exerts neuroprotective effects in Alzheimer's disease. *Alzheimers Res Ther.* 2026;18:Article 1961-5.
8. Koh SH, Liang AC, Takahashi Y, et al. Differential effects of Isoxazole-9 on neural stem/progenitor cells, oligodendrocyte precursor cells, and endothelial progenitor cells. *PLoS One.* 2015;10(9):e0138724.
9. Cayman Chemical. ISX-9 product data sheet. CAS 832115-62-5. Catalog 16165.
10. ISX9 loaded thermoresponsive nanoparticles for hair follicle regrowth. *Drug Deliv Transl Res.* 2024;14(2):537-549.
11. Ramirez-Rodriguez GB, Ortiz-Lopez L, Benitez-King GA. ISX-9 can potentiate cell proliferation and neuronal commitment in the rat dentate gyrus. *Neuroscience.* 2016;331:4-16.

12. Lorberbaum DS, Kishore S, Rosselot C, et al. Isoxazole alters metabolites and gene expression, decreasing proliferation and promoting a neuroendocrine phenotype in beta-cells. *Endocrinology*. 2017;158(1):127-138.
13. Pieper AA, Xie S, Capota E, et al. Discovery of a proneurogenic, neuroprotective chemical. *Cell*. 2010;142(1):39-51.
14. Bauman MD, Schumann CM, Carlson EL, et al. Neuroprotective efficacy of P7C3 compounds in primate hippocampus. *Transl Psychiatry*. 2018;8(1):202.
15. McIntyre RS, Johe K, Engel L, et al. Neuralstem, Inc. NSI-189 phosphate neurogenic compound: preclinical and clinical overview. Poster presented at: American College of Neuropsychopharmacology Annual Meeting; 2017.
16. Fava M, Johe K, Ereshefsky L, et al. A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder. *Mol Psychiatry*. 2019;24(5):768-777.
17. Jang SW, Liu X, Yepes M, et al. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. *Proc Natl Acad Sci U S A*. 2010;107(6):2687-2692.
18. Ring DB, Johnson KW, Henriksen EJ, et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. *Diabetes*. 2003;52(3):588-595.
19. McCoy AT, Benoist CC, Wright JW, et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. *J Pharmacol Exp Ther*. 2013;344(1):141-154.

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. ISX-9 has not been evaluated by any regulatory authority for safety or efficacy in humans. The compound has not entered clinical trials and no human pharmacokinetic, safety, or efficacy data exist. Investigators should obtain analytical confirmation of identity and purity on every lot. The cell-type-specific effects of ISX-9 (including cytotoxicity to oligodendrocyte precursor cells) should be considered in the design and interpretation of all experiments.